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Abstract
The utility of nitric oxide (NO)-releasing silica nanoparticles as a novel antibacterial is
demonstrated against Pseudomonas aeruginosa. Nitric oxide-releasing nanoparticles were prepared
via co-condensation of tetraalkoxysilane with aminoalkoxysilane modified with diazeniumdiolate
NO donors, allowing for the storage of large NO payloads. Comparison of the bactericidal
efficacy of the NO-releasing nanoparticles to 1-[2-(carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-
diolate (PROLI/NO), a small molecule NO donor, demonstrated enhanced bactericidal efficacy of
nanoparticle-derived NO and reduced cytotoxicity to healthy cells (mammalian fibroblasts).
Confocal microscopy revealed that fluorescently-labeled NO-releasing nanoparticles associated
with the bacteria, providing rationale for the enhanced bactericidal efficacy of the nanoparticles.
Intracellular NO concentrations were measurable when the NO was delivered from nanoparticles
as opposed to PROLI/NO. Collectively, these results demonstrate the advantage of delivering NO
via nanoparticles for antimicrobial applications.
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Antibiotic resistance has resulted in bacterial infections becoming the most common cause
of infectious disease-related death.1, 2 In the United States alone, nearly 2 million people per
year acquire infections during a hospital stay, of which approximately 90,000 die.2 The
primary culprits behind such deadly infections are antibiotic-resistant pathogens, which are
responsible for approximately 70% of all lethal nosocomial infections. The growing danger
of life-threatening infections and the rising economic burden of resistant bacteria have
created a demand for new antibacterial therapeutics.
The use of nanoparticles as delivery vehicles for bactericidal agents represents a new
paradigm in the design of antibacterial therapeutics. To date, most antibacterial
nanoparticles have been engineered using traditional antibiotics that are either incorporated
within the particle scaffold or attached to the exterior of the particle. In many cases, such
particles have exhibited greater efficacy than their constituent antibiotics alone. For
example, Gu et al. reported that vancomycin-capped gold nanoparticles exhibited a 64-fold
improvement in efficacy over vancomycin alone.3 Similarly, silver nanoparticles have
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shown greater antibacterial activity than silver ion (Ag+) in solution due to the direct toxicity
of the particles and tunable release of Ag+ based on nanocomposite size.4–6 Silica has also
been used as an antibacterial. Lin and co-workers employed mesoporous silica nanoparticles
to controllably release ionic liquids with proven bactericidal efficacy.7
While antibacterial nanoparticles have shown great promise, the use of conventional
antibiotics (e.g., vancomycin) or classical antibacterial agents (e.g., Ag+) does not address
bacterial resistance concerns.2, 8, 9 Nitric oxide (NO), a diatomic free radical that plays a key
role in the natural immune system response to infection,10 may represent an alternative
approach in the design of antibacterial nanoparticles. Macrophages and other inflammatory
cells produce NO to battle foreign microbes.11 In fact, mice lacking the ability to
endogenously produce NO are more susceptible to microbial infection.12 Nitric oxide has
been shown to possess broad spectrum antibacterial activity, primarily due to its reactive
byproducts such as peroxynitrite (ONOO−) and dinitrogen trioxide (N2O3).13 Both gram-
positive and gram-negative bacteria have been found to be susceptible to gaseous NO,
including methicillin-resistant Staphylococcus aureus (MRSA).14 The doses of NO required
to kill bacteria proved non-toxic to human dermal fibroblasts. Using diazeniumdiolate small
molecule NO donors, Raulli et al. reported the minimum inhibitory concentrations against
several bacterial species.15 These initial studies illustrate NO’s tremendous potential as an
antibacterial agent with broad spectrum activity.
Unfortunately, the utility of NO as an antibacterial agent is hindered by the lack of suitable
vehicles for NO storage and delivery. Indeed, NO is an extremely reactive gas and difficult
to administer as a therapeutic. To address delivery issues, Schoenfisch and coworkers have
synthesized nanoparticle-based scaffolds capable of storing large payloads of NO.16–18 The
nanoparticles spontaneously release tunable levels of NO under aqueous conditions at
physiological temperature and pH, and thus represent attractive vehicles for delivering NO.
Nanoparticle delivery of NO has two main advantages over previously-developed small
molecule NO donor systems (e.g., diazeniumdiolates, nitrosothiols, and metal-NO
complexes19, 20). First, the rate of NO release is easily modulated as a function of
nanoparticle size, composition, and/or surface hydrophobicity, thereby allowing for control
over the duration of NO release. Second, the versatility of the chemistry used to synthesize
the nanoparticles allows for specific tailoring of particles with functional groups to minimize
their toxicity and enable imaging and/or cell-specific targeting, while retaining the ability to
deliver therapeutic levels of NO. Herein, we report the efficacy of NO-releasing silica
nanoparticles against Pseudomonas aeruginosa, an opportunistic pathogen problematic in
burn and chronic wound infections.21–23 Both the bactericidal efficacy and cytotoxicity of
nanoparticle-derived NO is compared to NO release from a small molecule NO donor to
illustrate the advantage of delivering NO from silica nanoparticles.
Results and Discussion
Characterization of NO-releasing silica nanoparticles and PROLI/NO
Shin et al. previously reported the synthesis and characterization of NO-releasing silica
nanoparticles.24 Briefly, diazeniumdiolate NO donors were synthesized on
aminoalkoxysilane precursors prior to nanoparticle construction (Scheme 1), enabling the
formation of particles with superior NO release ability. By synthesizing diazeniumdiolate-
modified aminoalkoxysilanes prior to nanoparticle synthesis, particle aggregation was
reduced due to decreased hydrogen bonding interactions between amines. The synthesis
resulted in ~99% amine-to-diazeniumdiolate conversion efficiency and greater yields of NO
per mol of aminoalkoxysilane precursor compared to previous synthetic procedures used to
generate NO-releasing silica nanoparticles.18 29Si NMR spectroscopy of the AHAP3/NO
product was used to determine whether the presence of sodium methoxide would lead to
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self-condensation of the AHAP3/NO precursors during the diazeniumdiolate formation step
(Step 1 of Scheme 1). Notably, no significant Tn peaks characteristic of organosilane
polymerization were observed,18 indicating that the AHAP3/NO molecules did not pre-
condense under such reaction conditions. 1H NMR of AHAP3/NO revealed that the protons
adjacent to the secondary amine where diazeniumdiolate formation occurs became
deshielded in the presence of the zwitterionic NO donor, shifting downfield from 2.45 ppm
to 2.84 ppm. The presence of the diazeniumdiolate on AHAP3/NO was also confirmed via
UV-Vis spectroscopy (λmax = 253 nm, characteristic of the diazeniumdiolate absorption
maximum17, 25) and direct observation of the released NO via chemiluminescence.26
The presence of the diazeniumdiolate functional group in the nanoparticle scaffold was
confirmed via UV absorbance spectroscopy and the direct measurement of NO release. As
shown in Figure 1, diazeniumdiolate-modified 45 mol% AHAP3/TEOS silica nanoparticles
(Nanoparticle/NO) exhibited a similar λmax of 257 nm. Nitric oxide release due to
diazeniumdiolate decomposition27 was monitored in phosphate buffered saline (PBS; 10
mM, pH 7.4) at 37 °C using a chemiluminescence NO analyzer.26 As shown in Figure 2A,
the total amount of NO released (t[NO]) and maximum NO flux ([NO]m) from the AHAP3
nanoparticle system were ~3.8 μmol·mg−1 and ~21700 ppb·mg−1, respectively. The NO
release kinetics from the AHAP3 silica nanoparticles were relatively rapid compared to
other NO-releasing silica nanoparticle systems,18 with a NO release half life (t1/2) of 18 min.
As a result of the rapid NO release from the 45 mol% AHAP3 nanoparticles, the time
required to reach the maximum NO flux (tm) of ~21700 ppb·mg−1 was only 8 min after
immersion in buffer solution. The initial burst of NO allows for the relatively rapid delivery
of micromolar quantities of NO that produce the reactive nitrogen and oxygen species that
mediate NO’s bactericidal actions.28 As characterized by atomic force microscopy (AFM),
the size and homogeneity of the 45 mol% AHAP3 nanoparticles were 136 ± 15 nm
(Supporting Information). Both the size and NO-release properties of diazeniumdiolate-
modified silica nanoparticles proved tunable based on the amount and identity of
aminoalkoxysilane precursor employed in the synthesis (data not shown). A full systematic
characterization of such properties as a function of NO donor is reported elsewhere.24
To facilitate comparison of the bactericidal efficacy of nanoparticle-derived NO with small
molecule-derived NO, the amino acid proline was functionalized with diazeniumdiolate NO-
donors as described by Saavedra et al.29 As shown in Fig. 2B, the release of NO from
PROLI/NO was also extremely rapid, with a t1/2 of approximately 1.7 min. On a per mg
basis, PROLI/NO released less than half as much total NO as the AHAP3 nanoparticles,
with a t[NO] value of 1.8 μmol NO·mg−1. Due to its rapid NO release characteristics,
however, the [NO]m for PROLI/NO (>145000 ppb·mg−1) was more than 6 times greater
than the [NO]m generated by the nanoparticles per mg, with tm approximately 1 min after
addition to buffer. Despite the large bolus of NO released by PROLI/NO, the extended
duration of NO release from the AHAP3/TEOS nanoparticle system is more beneficial for
antibacterial applications because its NO release capabilities are not immediately lost upon
exposure to aqueous conditions. Indeed, effective NO-based antibacterial agents require NO
release durations long enough to allow the NO donor vehicle to reach the intended site of
action without becoming depleted of NO during transit, while still releasing bactericidal
quantities of NO.
Bactericidal efficacy under static conditions
The bactericidal efficacy of the 45 mol% AHAP3 NO-releasing silica nanoparticles was
evaluated against P. aeruginosa, an opportunistic gram-negative pathogen. Due to a
multitude of virulence factors, P. aeruginosa is a common cause of burn wound infections
leading to significant morbidity and mortality in burn wound victims.21,22 Additionally, P.
aeruginosa plagues >30% of all leg and foot ulcers resulting in chronic wounds with
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impaired healing.23 Perhaps most alarming, however, is the emergence of multidrug-
resistant P. aeruginosa that has been isolated from nosocomial burn wound patients.22, 30 P.
aeruginosa clones resistant to both β-lactams and aminoglycosides, two classes of antibiotics
that are commonly used to treat P. aeruginosa infections are documented.30 Thus, novel
treatments for combating infections resulting from antibiotic-resistant pathogens are
urgently needed. We hypothesized that the AHAP3/TEOS silica nanoparticle system,
capable of storing multiple NO donors within each delivery vehicle, may represent an
attractive new method for killing pathogenic bacteria due to its ability to release high
localized doses of NO. To determine the influence of the nanodelivery vehicle on the
antibacterial properties of NO, the bactericidal efficacy of 45 mol% AHAP3 nanoparticles
was compared to that of PROLI/NO. Although a previous study evaluated the antibacterial
properties of the small molecule NO-donor DETA/NO (diazeniumdiolate-modified
diethylenetriamine),15 we observed that the diethylenetriamine backbone alone
demonstrated considerable toxicity to P. aeruginosa (data not shown), which is consistent
with the observations of others.31 Conversely, the backbone of PROLI/NO (the amino acid
proline) exhibited no toxicity to P. aeruginosa up to 20 mg·mL−1, the highest concentrations
tested.
To facilitate direct comparison of the amount of NO necessary to kill P. aeruginosa, initial
studies were conducted in PBS. The bacterial killing assays conducted in aqueous buffer
demonstrate the bactericidal activity of NO under nutrient-free (“static”) conditions in which
the bacteria were unable to replicate. In this manner, the data collected were not convoluted
by the ability of the bacterial culture to proliferate in the medium during the experiment.
Bacterial killing assays were performed instead of the more conventional minimum
inhibitory concentration (MIC) assays in order to assess the extent to which NO actually
kills P. aeruginosa as opposed to simply inhibiting its growth. An understanding of these
parameters is important because it has been suggested that bactericidal agents are less likely
to foster resistance among pathogens than those that are simply bacteriostatic.32 As shown in
Figure 3, the concentrations of PROLI/NO and NO-releasing nanoparticles that proved
completely bactericidal (3 logs of killing) to P. aeruginosa were 2.5 mg·mL−1 and 70
μg·mL−1, respectively. Thus, by mass, approximately 35 times more PROLI/NO was
required than silica nanoparticles to completely kill all P. aeruginosa cells in the bacterial
suspension. Both the proline and 45 mol% AHAP3 silica controls depleted of NO exhibited
no killing of P. aeruginosa over the concentration ranges tested, indicating that the toxicity
observed from the NO-releasing analogues was due entirely to NO. Real-time
chemiluminescent detection of NO released from the two NO-donor systems (Fig. 2)
allowed for a direct comparison of the amount of NO released into solution over the 1 h time
course of the bactericidal assays. Of note, the amount of NO required per mL to elicit a 3 log
reduction in bacterial viability was markedly less from the nanoparticle scaffold than from
PROLI/NO (0.22 versus 4.5 μmol NO from nanoparticles and PROLI/NO, respectively).
The amount of NO delivered is expressed as total μmol NO released instead of a
concentration (e.g., mM) because the NO quickly reacts to form other reactive nitrogen and
oxygen species. As such, the exact molar concentration of NO and the byproducts in
solution are not known.
Time-based bactericidal assays under nutrient growth conditions
While the PBS-based bactericidal assays allow an uncomplicated comparison of the dose of
NO from both systems required to kill P. aeruginosa, they do not demonstrate the temporal
efficacy of each system, or accurately mimic a situation where the bacteria have the ability
to replicate. To better understand such parameters, time-based killing assays were performed
in tryptic soy broth (TSB) to test the bactericidal efficacy of NO-releasing silica
nanoparticles in a culture medium where the bacteria had the capacity to proliferate and
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present a competition between the rate of bacterial cell killing and replication. Such time-kill
studies offer valuable information regarding the temporal efficacy of antimicrobial agents.33
Conventional antibacterial susceptibility tests such as the MIC and minimum bactericidal
concentration (MBC) assays do not allow for acute temporal studies. In the TSB nutrient
medium, P. aeruginosa exposed to blank and control (proline and silica) solutions
proliferated over the 2 h experiment (Figure 4). As expected, the concentration of both NO-
releasing silica nanoparticles and PROLI/NO necessary to completely kill P. aeruginosa in
TSB was greater than the dose necessary to achieve the same result in PBS. This increase is
attributed to both the ability of P. aeruginosa to proliferate in TSB and the NO scavenging
properties of the protein digest that comprises TSB. Indeed, chemiluminescent NO release
measurements performed in TSB revealed that a significant amount of NO was scavenged
by the TSB media itself (Supporting Information), effectively lowering the amount of NO
able to act on the P. aeruginosa cells.
Despite the scavenging of NO and bacterial proliferation in TSB, complete bacterial killing
was still achieved, albeit at higher concentrations of both nanoparticles and PROLI/NO.
Similar to the experiments performed in PBS, the amount (by mass) of PROLI/NO
necessary to kill all P. aeruginosa was greater than that of NO-releasing nanoparticles.
Figure 4 illustrates the dose- and time-dependent bactericidal activity of both PROLI/NO
and NO-releasing silica nanoparticles. At a nanoparticle concentration of 400μg·mL−1,
~90% bactericidal efficacy was achieved after 2 h (one log reduction in viable P. aeruginosa;
Fig. 4B). Doubling the particle concentration to 800 μg·mL−1 resulted in 100% bacterial
killing over the same period (4 log reduction in viable P. aeruginosa). Complete bactericidal
activity was achieved in a shorter period (90 min) using significantly greater concentrations
of silica nanoparticles (3200 μg·mL−1). However, particle concentrations >3200 μg·mL−1
did not reduce the time necessary for 100% bacterial killing below 90 min (data not shown).
In contrast, PROLI/NO achieved more rapid bacterial killing than the 45 mol% AHAP3
nanoparticles, but at significantly greater concentrations. For example, a concentration of 12
mg·mL−1 PROLI/NO resulted in complete killing after only 30 min. The difference in the
rate of bacterial killing is attributed to the NO-release kinetics of each NO donor. The NO
release from PROLI/NO is rapid with a half life (t1/2) of 1.7 min, resulting in rapid (≤30
min) bacterial killing at 12 and 20 mg·mL−1. In contrast, the NO release kinetics from 45
mol% AHAP3 silica nanoparticles, which were unchanged in the presence of TSB, are
significantly longer (t1/2 = 18 min), thereby requiring longer incubation periods at 800 and
3200 μg·mL−1 to achieve complete bactericidal activity. Analogous to the results obtained
in PBS, complete bacterial killing required a markedly greater amount of NO per mL from
PROLI/NO (21.6 μmol) than from the NO-releasing silica nanoparticles (2.8 μmol).
A direct comparison of the amount of NO required from each vehicle to achieve 100%
bactericidal efficacy in both PBS and TSB is shown in Figure 5. Greater amounts of NO
were necessary in TSB to achieve complete bactericidal activity than from the same vehicles
in PBS due to both the ability of P. aeruginosa to proliferate in TSB and the NO-scavenging
properties of TSB as noted above. Regardless of the media, NO delivered from the
nanoparticles exhibited significantly greater bactericidal efficacy than NO delivered from
the small molecule diazeniumdiolate (i.e., PROLI/NO). Indeed, the amount of NO required
from PROLI/NO to completely kill P. aeruginosa was approximately one order of magnitude
greater than that required from the 45 mol% AHAP3 nanoparticles. Since the reactivity of
NO is largely dependent on its localized concentration and diffusion properties,34 NO
derived from a small molecule dispersed throughout solution is expected to possess slower
diffusion into bacterial cells and correspondingly lessened antibacterial activity compared to
the high localized concentrations of NO delivered by silica nanoparticles.
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To understand the enhanced bactericidal efficacy of NO delivered from nanoparticles
compared to PROLI/NO, fluorescein isothiocyanate (FITC)-modified silica nanoparticles
were synthesized to visually determine if any nanoparticle interaction with P. aeruginosa
cells existed. After synthesis of the nanoparticles, characteristic FITC fluorescence was
observed at 500 – 530 nm when the particles were excited at 488 nm. Incorporation of FITC
into the silica nanoparticle scaffold did not significantly alter the NO-release properties of
the nanoparticles (data not shown) or the particle diameter (124 ± 13 nm vs. 136 ± 15 nm
with and without FITC, respectively). Using the FITC-modified silica nanoparticles,
confocal fluorescence microscopy studies were conducted to determine if the enhanced
bactericidal efficacy of the nanoparticles was due to nanoparticle interaction with P.
aeruginosa cells. As shown in Figure 6, nanoparticles began to associate with the P.
aeruginosa cells as early as 10 min post-injection. The possible mechanism by which this
association occurs is not entirely understood, but most likely is attributed to electrostatic35
and/or hydrophobic36 interactions between the particles and bacterial membrane.
A NO-sensitive fluorescence probe, 4,5-diaminofluorescein diacetate (DAF-2 DA),37 was
employed to determine if the association between NO-releasing silica nanoparticles and P.
aeruginosa cells resulted in high local concentrations of NO and more efficient delivery of
NO to the bacterial cells. Once DAF-2 DA permeates the bacterial cell membrane,
intracellular esterases hydrolyze the acetate groups to generate the membrane-impermeable
DAF-2.37 In the presence of NO, DAF-2 is nitrosated by reactive nitrogen species (e.g.,
N2O3) and exhibits bright green intracellular fluorescence.37 Cells loaded with DAF-2 were
imaged in the presence of propidium iodide (PI), a nucleic acid viability dye that only enters
cells with compromised membranes. Inside the cell, PI exhibits strong red fluorescence upon
interaction with nucleic acid material. Red fluorescence due to PI entering cells with
disrupted plasma membranes thus indicates cell death.38 Prior to introduction of NO-
releasing silica nanoparticles, no autofluorescence was observed from either DAF-2 DA or
DAF-2. However, P. aeruginosa cells loaded with DAF-2 exposed to 100 μg·mL−1 NO-
releasing nanoparticles exhibited strong DAF-2 fluorescence (Fig. 7B–E), indicative of a
high localized concentration of NO in close proximity to the bacterial cells. As more NO
was released from the nanoparticles, the DAF-2 green fluorescence in each cell increased
progressively, indicating that the NO level inside each cell was increasing. After reaching a
peak intracellular intensity of DAF-2 fluorescence, PI then rapidly entered the bacterial cells
due to membrane disruption and cell death. The increase in PI fluorescence coincided with a
decrease in DAF-2 fluorescence (Fig. 7C–F), suggesting that the DAF-2 fluorophore leaked
from the cytosol through the damaged cell membrane that allowed PI to enter the cells.
In contrast to the strong intracellular green fluorescence observed from DAF-2 in the
presence of 100 μg·mL−1 NO-releasing silica nanoparticles, DAF-2 fluorescence was not
observed when an equal amount of NO was delivered with PROLI/NO (data not shown). As
indicated by the absence of any PI fluorescence from the bacterial cells over the same
period, P. aeruginosa cell death was not observed with this dose of NO from PROLI/NO,
thus reaffirming that doses of NO delivered from nanoparticle delivery vehicles were more
efficient at killing P. aeruginosa cells compared to similar doses from small molecule NO
donors. When the amount of PROLI/NO was increased to bactericidal levels (5 mg·mL−1),
rapid cell death was observed as evidenced by bright red intracellular PI fluorescence in the
confocal microscopy images (Supporting Information). However, DAF-2 fluorescence was
still not observed prior to cell death (in contrast to the nanoparticles), indicating that the NO
concentration surrounding the cells was not high enough to induce intracellular DAF-2
fluorescence. These data reveal that the delivery of NO is significantly more efficient from
silica nanoparticles. As such, lower doses of NO delivered from silica nanoparticles
effectively kill the bacteria.
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As shown in Figure 8, the ability of the nanoparticles to deliver appreciable NO payloads in
close proximity to the bacterial cells allows the NO to more efficiently target cellular
components (e.g., cell membrane, DNA, proteins, etc.) critical to cell function,
circumventing the need for NO to diffuse across large distances in solution to reach the cell.
As a lipophilic molecule, NO is capable of rapidly crossing cell membranes.13 The release
of high levels of NO at or near the cell membrane would be expected to lead to high
intracellular concentrations of NO. The antibacterial properties of NO and its reactive
byproducts have been thoroughly reviewed,13, 28, 39–41 and are typically ascribed to either
nitrosative or oxidative stress. In addition to causing DNA deamination, nitrosative species
such as N2O3 may nitrosate thiols (S-nitrosation) on proteins and initiate disulfide bridging
with other thiols on the protein,42 thereby directly altering protein function.13 Due to their
lipophilic nature, NO and O2 tend to concentrate in cell membranes, accelerating NO’s
oxidation to N2O3 and creating greater nitrosative stress within and near the bacterial
membrane.41 Nitrosation of both cell surface proteins and intracellular proteins (including
enzymes) has been shown to cause bacterial cell death.13 Oxidative stress is driven primarily
by peroxynitrite (ONOO−), which forms via the reaction of NO with superoxide
endogenously derived from the bacterial cellular respiration process.13, 43–46 Thus, oxidative
damage is expected to occur predominantly inside the cell, since superoxide does not readily
cross cell membranes.47 A significant antibacterial process related to oxidative stress is
peroxynitrite-dependent lipid peroxidation, which stems from OH and NO2 radicals derived
from peroxynitrous acid (HOONO; Fig. 8).48 The production of NO2 radical from NO and
O2 is also accelerated in membranes, leading to even greater NO-mediated oxidative stress
within bacterial cell membranes.41 Membrane destruction via lipid peroxidation has been
proposed as one of the major mechanisms of NO-mediated bactericidal activity. As a
peroxynitrite-dependent process requiring superoxide, NO released in close proximity to a
bacterial cell would be expected to exert greater bactericidal effects than NO released
diffusely throughout solution by generating a larger intracellular NO concentration.13
Indeed, we observed direct evidence of membrane destruction during the confocal
microscopy experiments by the rapid appearance of intracellular PI fluorescence (Fig. 7) in
cells treated with NO-releasing silica nanoparticles. By virtue of the extended NO-release
half-life of the silica nanoparticles relative to PROLI/NO, a significant portion of the NO is
retained until after particle association with the P. aeruginosa cells. Such high localized NO
release in close proximity to the bacterial cells may then facilitate delivery of greater
concentrations of NO and other reactive species to the cell membrane and into the cell itself,
leading to enhanced bactericidal efficacy of NO delivered from nanoparticles.
Cytotoxicity of AHAP3 nanoparticles and PROLI/NO against L929 mouse fibroblasts
The significant toxicity that NO-releasing 45 mol% AHAP3 silica nanoparticles exhibited
against P. aeruginosa cells demands study of their effect on healthy mammalian cells as
well. Although Ghaffari et al. have demonstrated that NO gas (200 ppm for 4 h) was not
toxic to human dermal fibroblasts,14 similar studies were conducted to determine the
combined effects of NO and the silica nanoparticle scaffold on L929 mouse fibroblast cells.
Such cells represent the standard for cytotoxicity testing of novel therapeutic agents.49, 50
Survival of the L929 cells in the presence of control and NO-releasing silica nanoparticles
was monitored via both propidium iodide (PI) and lactate dehydrogenase (LDH) viability
assays over 2 h to mimic the time-based bactericidal assays described above. As discussed
above, healthy cells with uncompromised membranes exclude PI in the buffer solution,
while disrupted plasma membranes allow PI to diffuse into the cell and emit characteristic
fluorescence after complexation with intracellular nucleic acids.38 Positive detection of
LDH in the culture medium also indicates compromised cellular membranes that allow
larger proteins to leak out of the cell, further indicating membrane disruption and cell death.
Both assays thus monitor membrane permeability to assess cell viability, a suitable method
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to assay for the destructive properties of reactive NO byproducts that are known to form in
greater quantities at lipid membranes.41 A range of nanoparticle concentrations was tested to
encompass the bactericidal concentrations of 45 mol% AHAP3 silica in the PBS and TSB
assays (70 μg·mL−1 and 800 μg·mL−1, respectively). As shown in Figure 9, both control and
NO-releasing 45 mol% AHAP3 silica nanoparticles were found to present minimal toxicity
to the L929 fibroblasts. Remarkably, when exposed to the same concentration of NO-
releasing silica nanoparticles required to induce 4 logs of bacterial killing (800 μg·mL−1;
Fig. 4B), L929 cells maintained 92% viability as measured by the PI assay. Thus, P.
aeruginosa appears to be extremely susceptible to NO-releasing silica nanoparticles, while
such delivery vehicles pose minimal threat to healthy mammalian fibroblasts.
In contrast, PROLI/NO proved toxic to L929 fibroblasts when administered at
concentrations required to kill P. aeruginosa. When L929 cells were exposed to the dose of
PROLI/NO required to induce 4 logs of bacterial killing in TSB within 2 h (12 mg·mL−1;
Fig. 4A), 100% cell death (i.e., 0% viability) was observed within 45 min (Figure 10). While
proline, (the precursor of PROLI/NO) exhibited no toxicity to L929 fibroblasts at
concentrations up to 16 mg·mL−1 (data not shown), 100% fibroblast cell death was observed
within 90 min at a PROLI/NO concentration of 8 mg·mL−1. Upon reducing the PROLI/NO
concentration to 4 mg·mL−1, 100% fibroblast viability was maintained through 2 h, but at
the expense of bactericidal efficacy (Fig. 4A). These results reinforce the advantages of
delivering NO via nanoparticle scaffolds, as both the amount of NO necessary to kill
bacteria and toxicity to healthy mammalian cells are reduced.
Conclusions
Nitric oxide delivered from silica nanoparticles was shown to be significantly more effective
at killing pathogenic P. aeruginosa than NO derived from the small molecule NO donor
PROLI/NO. Indeed, significantly less NO was required from the nanoparticles to kill P.
aeruginosa than from PROLI/NO, even though the initial NO release from PROLI/NO was
6-fold greater than from 45 mol% AHAP3 silica nanoparticles. In vitro cytotoxicity
experiments conducted with L929 mouse fibroblasts confirmed that NO-releasing silica
nanoparticles are largely non-toxic to mammalian fibroblast cells at concentrations capable
of killing P. aeruginosa, while PROLI/NO presents significant toxicity to such cells when
administered at bactericidal concentrations. Such results demonstrate the promise that NO
holds as a new strategy for battling bacterial infection. Confirmation of particle association
with P. aeruginosa cells and the measurement of intracellular NO levels helped elucidate the
differential toxicity observed between macromolecular and small molecule NO donors. The
versatility in the synthesis of NO-releasing silica scaffolds allows for both tuning of size and
exterior functionality that may further enhance their use as antibacterial agents. Future
studies are aimed at identifying the intracellular location of the reactive radical species
formed upon NO release and establishing a mechanistic understanding of the interactions
between NO-releasing nanoparticles and bacterial cell membranes. As well, experiments are
underway to evaluate the antibacterial properties of NO-releasing silica nanoparticles
against other species of pathogenic bacteria including gram-positive strains and those that
exhibit resistance to conventional antibiotics.
Methods
Materials
Tetraethoxysilane (TEOS) and sodium methoxide (NaOCH3) were purchased from Fluka
(Buchs, Switzerland). N-(6-Aminohexyl)aminopropyltrimethoxysilane (AHAP3) and 3-
aminopropyltrimethoxysilane (APTMS) were purchased from Gelest (Tullytown, PA).
Methanol (MeOH), ethanol (EtOH), and ammonia solution (NH4OH, 30 wt% in water) were
Hetrick et al. Page 8













purchased from Fisher Scientific (Fair Lawn, NJ). Tryptic soy broth (TSB, soybean-casein
digest) was purchased from Becton, Dickinson and Company (Sparks, MD). Nitric oxide
(NO, 99.5%) was obtained from Linde (Raleigh, NC), and argon (Ar) and nitrogen (N2)
gases were purchased from National Welders (Raleigh, NC). P. aeruginosa (ATCC #19143)
and L929 mouse fibroblast cells were purchased from American Type Culture Collection
(Manassas, VA). 4,5-Diaminofluorescein diacetate (DAF-2 DA) was purchased from
Calbiochem (San Diego, CA). Fluorescein isothiocyanate (FITC), proline and reagents for
the propidium iodide and lactate dehydrogenase cytotoxicity assays were purchased from
Sigma (St. Louis, MO). Other solvents and chemicals were analytical-reagent grade and
used as received. A Millipore Milli-Q UV Gradient A-10 System (Bedford, MA) was used
to purify distilled water to a final resistivity of 18.2 MΩ·cm and a total organic content of ≤6
ppb.
Synthesis of NO-releasing silica nanoparticles
The synthesis and characterization of NO-releasing silica nanoparticles has been described
previously.18 Briefly, an aminoalkoxysilane solution was prepared by dissolving AHAP3
(2.3 mmol) in 20 mL of EtOH and 4 mL of MeOH in the presence of NaOCH3 (2.3 mmol).
The solution was then placed into 10 mL vials equipped with stir bars. The vials were placed
in a Parr bottle, connected to an in-house NO reactor, and flushed with Ar six times to
remove O2 in the solution. The reaction bottle was pressurized to 5 atm NO for 3 d with
continuous stirring of the silane solution. Prior to removing the diazeniumdiolate-modified
AHAP3 silane sample (AHAP3/NO), unreacted NO was purged from the chamber with Ar.
Silane solutions were prepared by mixing TEOS (2.8 mmol) and AHAP3/NO (2.3 mmol;
corresponding to 45 mol%, balance TEOS) in the EtOH/MeOH solution for 2 min (Scheme
1). The silane solution was then added into 22 mL of EtOH and 6 mL ammonia catalyst (30
wt% in water), and mixed vigorously for 30 min at 4 °C. The precipitated nanoparticles were
collected by centrifugation (5000 rpm, 5 min), washed with EtOH several times, dried under
ambient conditions for 1 h, and stored in a sealed container at −20 °C until used.
Diazeniumdiolate incorporation into the nanoparticle scaffold was confirmed by UV
absorbance spectroscopy. The UV absorbance spectra of nanoparticles (both NO-releasing
and controls depleted of diazeniumdiolates) suspended in phosphate buffered saline (PBS) at
160 μg·mL−1 were recorded on a Perkin-Elmer Lambda 40 UV/Vis Spectrometer.
Characterization of diazeniumdiolate-modified silane (AHAP3/NO)
1H NMR (CD3OD, δ): 0.61 (br, SiCH2), 1.32 (qt, NRCH2CH2CH2CH2CH2CH2NH2), 1.43
(m, SiCH2CH2CH2, NRCH2CH2), 1.56 (m, CH2CH2NH2), 2.56 (m, CH2CH2NH2), 2.84
(br,CH2NRCH2), 4.88 (s, Si(OCH3)3) where R = NONO−Na+. UV-Vis (EtOH): λmax = 253
nm. 29Si nuclear magnetic resonance (NMR) spectroscopy was also employed to
characterize AHAP3/NO. Cross-polarization/magic angle spinning (CP/MAS) 29Si NMR
spectra of the AHAP3/NO were obtained at 20 °C on a Bruker 360 MHz DMX spectrometer
(Billerica, MA) equipped with wide-bore magnets (triple-axis pulsed field gradient double-
resonance probes). The alcoholic solution of diazeniumdiolate-modified silane (i.e.,
AHAP3/NO) was loaded into 4 mm rotors (double-resonance frequency of 71.548 MHz)
and spun at a speed of 8.0 kHz. The chemical shifts were determined in ppm relative to a
TMS external standard.
Synthesis of fluorescently-labeled NO-releasing silica nanoparticles
The synthesis of fluorescently-labeled NO-releasing silica nanoparticles was adapted from a
previously reported literature procedure.51 Briefly, FITC (10 μmol) was reacted with neat
APTMS (200 μmol) overnight in the dark to yield the FITC-modified silane. 1H NMR
(CD3OD, δ): 0.32 (br, SiCH2), 1.52 (qt, SiCH2CH2CH2NH-FITC), 2.73 (t,
SiCH2CH2CH2NH-FITC), 3.69 (m, SiCH2CH2CH2NH-FITC), 4.81 (s, Si(OCH3)3), 6.46
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(m, aromatic), 7.01 (m, aromatic) 7.11 (d, aromatic) 7.45 (d, aromatic) 7.57 (d, aromatic).
UV-Vis (EtOH): λmax = 493 nm.
Next, 100 μL of the FITC-modified silane solution was co-condensed with AHAP3/NO (2.3
mmol) and TEOS (2.8 mmol) in the EtOH/ammonia solution as described above to yield
FITC-labeled NO-releasing silica nanoparticles (Supporting Information). Incorporation of
FITC was confirmed by exciting the particles at 488 nm and observing the characteristic
fluorescence due to FITC at 500 – 530 nm.
Size characterization of silica nanoparticles
The size of control, NO-releasing, and FITC-modified silica nanoparticles was characterized
via atomic force microscopy (AFM). Prior to analysis, the particles were suspended in
toluene, deposited on a freshly cleaved mica surface (SPI; West Chester, PA), and dried
under ambient conditions for 3 h. Contact mode AFM images were obtained in air using a
Molecular Force Probe 3D AFM (Asylum Research; Santa Barbara, CA) controlled with
MFP-3D software running under Igor Pro (Wavemetrics; Lake Oswego, OR). Triangular
silicon nitride cantilevers with a nominal spring constant of 0.12 N·m−1 and resonance
frequency of 20 kHz (Veeco; Santa Barbara, CA) were used to acquire height/topography
images at a scan rate of 1.0 Hz.
Synthesis of 1-[2-(carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolate (PROLI/NO)
(adapted from a previously reported procedure29)
Proline (300 mg, 2.6 mmol) was dissolved in a 50:50 mixture of methanol:ether and treated
with 281 mg (5.2 mmol) of NaOCH3. The basic solution was placed in a glass
hydrogenation bomb and stirred. The bomb was copiously flushed with Ar to remove
atmospheric O2, followed by introduction of NO gas at 5 atm. After 3 d, the glass vial was
removed from the vessel after thorough flushing with Ar. The solution was treated with cold
ether to precipitate the product (PROLI/NO). The NO donor precipitate was then filtered,
and dried under vacuum at −70 °C (dry ice/acetone bath) to yield 299 mg PROLI/NO.
Nitric oxide release measurements
Nitric oxide release from both the diazeniumdiolate-modified silica nanoparticles and
PROLI/NO was measured in deoxygenated phosphate-buffered saline (PBS, 0.01 M; 37 °C)
at pH 7.4 using a Sievers NOA 280i chemiluminescence NO analyzer (Boulder, CO). Nitric
oxide released from the donors was transported to the analyzer by a stream of N2 (70
mL·min−1) passed through the reaction cell. The instrument was calibrated with air passed
through a NO zero filter (0 ppm NO) and a 24.1 ppm NO standard gas (balance N2).
Bactericidal assays under static conditions
To test the bactericidal properties of PROLI/NO and NO-releasing 45 mol% AHAP3/TEOS
silica nanoparticles under non-growth (“static”) conditions, P. aeruginosa was cultured to a
concentration of 108 colony-forming-units (CFUs) per mL in tryptic soy broth (TSB),
resuspended in sterile PBS, and adjusted to a concentration of 103 CFU·mL−1. Silica
nanoparticles (NO-releasing and control), PROLI/NO, and proline were added to separate
aliquots of the bacterial suspension over a concentration range optimized for each system.
After 1 h incubation at 37 °C with gentle agitation, 100-μL aliquots from each suspension
were plated on tryptic soy agar. After overnight incubation at 37 °C, the colonies on each
plate were counted, allowing for calculation of the number of viable P. aeruginosa cells in
each vial at the time of plating.
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Time-based bactericidal assays under nutrient growth conditions
To test the temporal efficacy of the NO-releasing silica nanoparticles, time-based
antibacterial assays were conducted in TSB nutrient media. P. aeruginosa was cultured in
TSB to a concentration of 108 CFU·mL−1 and diluted to 104 CFU·mL−1 in additional TSB.
Silica nanoparticles (control and NO-releasing), PROLI/NO, and proline were added to
separate aliquots of the 104 bacterial suspension over concentration ranges optimized for
each system. Every 30 min for 2 h, 100-μL aliquots of each suspension were removed,
diluted 10-fold in PBS, and plated on tryptic soy agar. Bacterial viability was determined as
described above after incubating the plates overnight at 37 °C.
Interaction between nanoparticles and bacterial cells
P. aeruginosa was cultured in TSB to 108 CFU·mL−1, pelleted by centrifugation,
resuspended in PBS, and adjusted to a concentration of 106 CFU·mL−1 in PBS. The bacterial
suspension was seeded onto a glass microscope slide where the bacteria were allowed to
adhere to the slide for 30 min. The microscope slide was placed on the stage of a Zeiss LSM
510 confocal fluorescence microscope (Chester, VA) and bright-field and fluorescence
images of the bacteria were acquired with a 63x N.A. 1.4 planapochromat oil immersion
lens. Next, an aliquot of FITC-modified NO-releasing silica nanoparticles (final
concentration = 100 μg·mL−1) was added and bright-field and fluorescence images of the
same field were captured after 0, 10, 20, 30, and 60 min. The FITC fluorophores were
excited with the 488 nm line of an Ar laser and the fluorescence was collected using a BP
500–530 nm bandpass filter.
Confocal fluorescence microscopy for detection of intracellular NO and cell killing
Confocal microscopy experiments were conducted to simultaneously monitor intracellular
concentrations of NO within P. aeruginosa cells and the kinetics of cell killing using 4,5-
diaminofluorescein diacetate (DAF-2 DA, a NO-sensitive fluorescence probe), and
propidium iodide (PI, a fluorescence viability dye that enters only cells with compromised
membranes and emits bright red fluorescence after binding to DNA38). An aliquot of P.
aeruginosa, cultured as described above, was resuspended at 106 CFU·mL−1 in PBS
supplemented with DAF-2 DA (10 μM) and incubated at 37 °C for 30 min. 500 μL of the
cells loaded with DAF-2 were transferred onto a glass microscope slide affixed in a circular
microscope cell to allow capture of initial images. 500 μL of PBS containing 10 μM DAF-2
DA, 60 μM PI and either NO-releasing silica nanoparticles (200 μg·mL−1) or PROLI/NO
(388 μg·mL−1) was then introduced. Images were immediately collected with a 63x
objective every minute for 2.5 h. The fluorescent reaction product of NO and DAF-2
(excitation λmax = 495 nm, emission λmax = 515 nm)37 was excited with the 488 line of an
argon laser. Fluorescence was collected using a BP 500–530 nm bandpass filter. PI
fluorescence was excited with the 543 nm line of a HeNe laser and collected with a long-
pass (LP 560) filter. All confocal microscopy experiments were performed at 25 °C. At 25
°C, the half life of NO release from 45 mol% AHAP3 silica nanoparticles increased to >1 h.
Thus, the initial level of NO release was reduced, extending the duration of NO release.
Propidium iodide cytotoxicity assay
L929 mouse fibroblasts were plated on 24-well tissue culture treated dishes (BD Bioscience
#353047) at a density of 3.0 × 105 cells·mL−1 (150 × 103 cells per well) and incubated
overnight at 37 °C in 5% CO2/95% air. For the PI assay, the incubation buffer (Minimum
Essential Medium) was aspirated from each of the wells and replaced with 500 μL of Krebs-
Ringer-HEPES (KRH) buffer containing 115 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM
KH2PO4, 1.2 mM MgSO4, 25 mM HEPES, pH 7.4, supplemented with 30 μM PI.52 Control
or NO-releasing silica nanoparticles were added to the wells at 0, 50, 200, 400, 600, 800, or
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1000 μg·mL−1, or PROLI/NO was added at 0, 4, 8, or 12 mg·mL−1. The fluorescence
resulting from PI complexation with intracellular nucleic acid material38 in cells with
compromised membranes was acquired for a total of 120 min. Upon completion of these
measurements, the cells were incubated with digitonin (40 μM) for 20 min to completely
permeabilize the plasma membranes and achieve a maximum PI fluorescence. Cell viability
is presented as the increase in PI fluorescence from each well expressed as the percentage of
maximal fluorescence obtained from cells treated with digitonin (100% cell death).
Lactate dehydrogenase cytotoxicity assay
The lactate dehydrogenase (LDH) cytotoxicity assay was performed concomitantly with the
same cells used for the PI assay described above. Every 15 min, 20-μL aliquots of KRH
buffer were removed from the plate used for the PI assay and stored at −20 °C in black 96-
well plates (Greiner; Monroe, NC) for subsequent LDH analysis. The 96-well plates
containing aliquots of incubation buffer were warmed to 37 °C. Lactate dehydrogenase
activity was measured from the rate of NADH production after adding 180 μL of KRH
buffer containing 0.22 mM NAD+, 11.1 mM sodium lactate and 11.1 mM hydrazine, pH 8.0
into each well.53 The NADH fluorescence was monitored with a FluoStar Galaxy plate
reader using 340 nm excitation and 460 nm emission filters. The LDH activity is expressed
as the change in relative fluorescence per min per well. The data are normalized to maximal
LDH activity in each well obtained from samples treated with 40 μM digitonin for 20 min.
Statistics
For the bactericidal assays conducted in PBS, n = 3 and data are expressed as mean values ±
standard deviation. Data from both the PI and LDH cytotoxicity assays are presented as
mean values ± standard error of the mean.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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UV absorbance of control and diazeniumdiolate-modified (Nanoparticle/NO) 45 mol%
AHAP3/TEOS silica nanoparticles (concentration = 160 μg/mL in phosphate buffered
saline).
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Nitric oxide release profiles of (A) 45 mol% AHAP3 silica nanoparticles and (B) PROLI/
NO in PBS, pH 7.4, 37 °C. Inset of (A) represents total NO release. [NO]m = maximum NO
flux; tm = time to reach maximum NO flux; t[NO] = total NO released; t1/2 = half life of NO
release.
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Bactericidal efficacy of (A) proline and PROLI/NO and (B) control and NO-releasing 45
mol% AHAP3 silica nanoparticles (balance TEOS) against P. aeruginosa in phosphate
buffered saline.
Hetrick et al. Page 18














Time- and concentration-based bactericidal efficacy of (A) proline (control) and PROLI/NO
and (B) control (Nanoparticle) and NO-releasing 45 mol% AHAP3 silica nanoparticles
(Nanoparticle/NO).
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Comparison of the NO doses necessary from silica nanoparticles (dark blue) and PROLI/NO
(grey) to achieve 100% bactericidal efficacy against P. aeruginosa in (A) PBS and (B) TSB.
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Scanning confocal microscopy images of FITC-modified NO-releasing silica nanoparticle
association with P. aeruginosa cells. Images were acquired in bright-field mode (A–E) and
on the FITC fluorescence channel (A′–E′) before injection (A, A′) of 100 μg·mL−1 NO-
releasing FITC-modified AHAP3 silica nanoparticles, and 10 (B, B′), 20 (C, C′), 30 (D, D
′), and 60 (E, E′) minutes post-injection.
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Intracellular DAF-2 (green) and propidium iodide (red) fluorescence from P. aeruginosa
bacterial cells incubated with 100 μg·mL−1 45 mol% AHAP3/TEOS NO-releasing silica
nanoparticles. DAF-2 fluorescence indicates the presence of NO and reactive nitrogen
species, while propidium iodide fluorescence indicates membrane destruction and cell death.
Images were acquired (A) 30 min, (B) 83 min, (C) 113 min, (D) 124 min, (E) 132 min, and
(F) 140 min after nanoparticle addition.
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Proposed mechanisms by which NO acts as an antibacterial agent (adapted from references
13, 28, 39–41; not to scale). NO’s antibacterial properties are attributed to both nitrosative
and oxidative stress exerted by reactive byproducts such as N2O3 and ONOO−
(peroxynitrite). Nitrosative stress leads in part to nitrosation of thiols on proteins as well as
DNA deamination, while oxidative stress is responsible for membrane destruction via lipid
peroxidation. Notably, increased NO and O2 concentrations in lipid membranes leads to
enhanced production of both nitrosative and oxidative species such as N2O3 and NO2 in the
membrane.
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Toxicity of 45 mol% AHAP3 control (dark gray) and NO-releasing (light gray) silica
nanoparticles to L929 mouse fibroblasts as measured by (A) membrane permeability to
propidium iodide and (B) lactate dehydrogenase leaching.
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Cytotoxicity of PROLI/NO against L929 fibroblast cells as measured by propidium iodide
viability assay. The backbone of PROLI/NO (the amino acid proline) demonstrated no
toxicity to L929 cells at concentrations up to 16 mg/mL.
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Synthesis of AHAP3 NO donor and co-condensation with TEOS to form NO-releasing silica
nanoparticles. R=(CH2)3Si≡ and R′=H2N(CH2)6–.
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